Once again, stocks have delivered an upset. Despite the havoc wreaked by COVID-19 during the second quarter, corporate profits have generally been better-than-expected.
Sarepta Therapeutics (SRPT) has announced that it has teamed up with Codiak BioSciences to design and develop engineered exosome therapeutics to deliver gene therapy, …
Sarepta Therapeutics (SRPT) has reported weaker-than-expected earning results for the first quarter. Specifically, Q1 Non-GAAP EPS of -$1.
For those who like patterns, biotech names’ growth stories tend to look remarkably similar. These stocks are less reliant on earnings reports and …
There’s a new FDA-approved DMD medication on the scene. On Friday, the FDA green-lighted Sarepta Therapeutics’ (SRPT) Vyondys 53, the company’s treatment for …
Since 1986, Farallon Capital has built a proven record for success, mainly from steady hands at the helm and consistent returns for investors. …
After a period of uncertainty, confidence has returned to the market and sent stock prices soaring. This begs the question, have stocks soared …
On Monday, when the FDA came out against Sarepta Therapeutics’ (SRPT) Duchenne muscular dystrophy drug Vyondys 53, investors knew the shockwaves would immediately …
In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
Christmas is over and it seems like people spent their gift money on stocks… Sarepta Therapeutics (SRPT) stock rose over 10% is the …